



ASX AND MEDIA RELEASE

Wayne Goss to retire as Peplin director

BRISBANE, Australia, 30 August 2005: Peplin Limited (ASX:PEP) today announced Mr Wayne Goss would retire as a non-executive director of Peplin at this year's annual general meeting.

Mr Goss's decision to retire as a director of Peplin is due to an increase in other work commitments. He was appointed the national chairman of professional services firm Deloitte Touche Tohmatsu in June this year.

Mr Goss, who was Queensland's premier for six years to 1996 and served as a Peplin director since the company's IPO in 2000, said he had enjoyed and valued his time on Peplin's Board.

"Peplin is in excellent shape for the future after many years of effort by a dedicated and talented team which shares a strong belief in the value potential of the company's core technology," Mr Goss said

"The company is in very capable hands and I will continue to be a supporter of Peplin as I have every confidence in the company's future success," he said.

Peplin Chairman Dr Cherrell Hirst said the Board sincerely thanked Mr Goss for his dedication and contribution to the company over the past five years.

"Wayne helped guide Peplin through our formative years. We now have our lead product for actinic keratosis and non-melanoma skin cancer currently undergoing three clinical trials around Australia, and we are advancing our leukemia product towards clinical trials to commence next year," Dr Hirst said.

"Wayne can be proud of his contribution to the past and future success of Peplin," she said.

Dr Hirst said Peplin is actively broadening the skill set of the Board and would add further international and industry experience to its ranks.

ENDS

ABOUT PEPLIN

Peplin is focused on the development and commercialisation of prescription human therapeutic products for the treatment of cancer. Its lead compound PEP005 is the first in a new class of investigational agents targeting various forms of cancer. Peplin's lead product is PEP005 Topical, which is being studied in phase IIa clinical trials for the treatment of actinic keratosis (a pre-cancerous lesion) and non-melanoma skin cancer. PEP005 Topical works by a powerful mode of action, directly killing most cancer cells and then recruiting and activating the local immune system to clean-up these dead cancer cells and kill any remaining cancer cells. PEP005 Topical is potentially a rapidly acting and cosmetically attractive non-surgical treatment for actinic keratosis and non-melanoma skin cancer. Peplin's product development activities are supported by the Australian Federal Government under its Pharmaceuticals Partnerships Program.

Peplin's earlier stage pipeline is targeted at leukemia (a blood borne cancer) using its lead compound PEP005 in an intravenous formulation (PEP005 IV) and bladder cancer using an intra-cavitary or intravesical formulation (PEP005 IC). PEP005 has demonstrated selective and potent anti-leukemia activity in pre-clinical disease models. PEP005 induces apoptosis in leukemia cells via the activation of PKC delta. Peplin holds global proprietary rights for PEP005 Topical and other oncology applications of PEP005. Its research portfolio of EPUFA compounds opens additional potential opportunities particularly in cancer and pain.

Further information:

Michael Aldridge
Managing Director & CEO
Tel: 07-3250 1200
michael.aldridge@peplin.com

Media enquiries:

Lisa Watson
Phillips Group
Tel: 07-3230 5000
lwatson@phillipsgroup.com.au